| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8953246 | European Urology Oncology | 2018 | 8 Pages |
Abstract
In this review we discuss current limitations in the use of urinary markers for detection and surveillance of bladder cancer. We identify potential studies that could demonstrate a clinical benefit of the use of markers in improving detection of bladder cancer by reducing evaluation of patients unlikely to have cancer or expediting identification of cancer. For surveillance, a marker trial could improve identification of bladder cancer or reduce cystoscopy in patients with low risk.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S. Cookson, Siamak Daneshmand, Ashish M. Kamat, James M. McKiernan, Raj S. Pruthi, Chad R. Ritch, Gary D. Steinberg, Robert S. Svatek, Ellen C. Zwarthoff,